Moderna (MRNA) Current Deferred Revenue (2017 - 2026)
Moderna (MRNA) posted quarterly Current Deferred Revenue of $442.0 million for Q2 2026, up 56.18% year-over-year from $283.0 million in Q2 2025, and up 72.66% on a QoQ basis from $256.0 million in Q1 2026.
Moderna (MRNA) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Moderna has reported Current Deferred Revenue for 10 years, with the latest figure at $442.0 million in Q2 2026.
- Current Deferred Revenue for Q2 2026 came in at $442.0 million, up 56.18% year-over-year; the trailing twelve-month figure through Jun 2026 was $442.0 million (up 56.18% YoY), and the FY2025 annual result was $252.0 million, up 19.43% from the prior year.
- Current Deferred Revenue climbed to $442.0 million in Q2 2026, from $256.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $6.1 billion in Q1 2022 and troughed at $20.0 million in Q2 2024.
- A 5-year average of $1.5 billion and a median of $562.5 million in 2023 frame the typical range for Current Deferred Revenue.
- The widest annual swing landed in 2024, when Current Deferred Revenue tumbled 98.85%; it then surged 1315.0% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $2.7 billion in 2022, then slumped by 75.99% to $651.0 million in 2023, then tumbled by 67.59% to $211.0 million in 2024, then advanced by 19.43% to $252.0 million in 2025, then surged by 75.4% to $442.0 million in 2026.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $442.0 million in Q2 2026, $256.0 million in Q1 2026, and $252.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 442.00 Mn |
| Mar 31, 2026 | 256.00 Mn |
| Dec 31, 2025 | 99.00 Mn |
| Sep 30, 2025 | 320.00 Mn |
| Jun 30, 2025 | 283.00 Mn |
| Mar 31, 2025 | 125.00 Mn |
| Dec 31, 2024 | 211.00 Mn |
| Sep 30, 2024 | 379.00 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Mar 31, 2024 | 750.00 Mn |
| Dec 31, 2023 | 651.00 Mn |
| Sep 30, 2023 | 1.37 Bn |
| Jun 30, 2023 | 1.73 Bn |
| Mar 31, 2023 | 1.22 Bn |
| Dec 31, 2022 | 2.04 Bn |
| Sep 30, 2022 | 4.18 Bn |
| Jun 30, 2022 | 4.09 Bn |
| Mar 31, 2022 | 6.06 Bn |
| Dec 31, 2021 | 6.25 Bn |
| Sep 30, 2021 | 8.48 Bn |